Associated Papers
SMAD4 and KRAS Status Shapes Cancer Cell-Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer.
Lloyd EG et al.
Cancer Research, 2025
39841099 (PubMed )
Supplement: EMS202804-supplement-Table_1.xlsx › Table_S1
Genomic landscape of gallbladder cancer: insights from whole exome sequencing.
Awasthi S et al.
International Journal of Surgery (london, England), 2024
Tumor organoids improve mutation detection of pancreatic ductal adenocarcinoma.
Farshadi EA et al.
Scientific Reports, 2024
39462012 (PubMed )
Supplement: 41598_2024_75888_MOESM2_ESM.xlsx › Figure2
Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
Li T et al.
Cancer Medicine, 2024
38770632 (PubMed )
Supplement: CAM4-13-e7227-s001.xlsx › Table_S2
TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma.
Zhou Y et al.
Journal of Translational Medicine, 2023
38037073 (PubMed )
Supplement: 12967_2023_4742_MOESM1_ESM.xlsx › Sheet1
Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer.
Lo A et al.
Bmc Cancer, 2022
Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study.
Shen F et al.
Frontiers in Oncology, 2022
35814426 (PubMed )
Supplement: DataSheet_1.xlsx › Table_S2
Genomic landscape of lung cancer in the young.
Ruiz R et al.
Frontiers in Oncology, 2022
36263208 (PubMed )
Supplement: DataSheet_2.pdf
Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA.
Finkle JD et al.
Npj Precision Oncology, 2021
34215841 (PubMed )
Supplement: 41698_2021_202_MOESM1_ESM.pdf
Identification of Altered Genes in Gallbladder Cancer as Potential Driver Mutations for Diagnostic and Prognostic Purposes: A Computational Approach.
D'Afonseca V et al.
Cancer Informatics, 2020
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
Goh G et al.
Plos Medicine, 2016
27923043 (PubMed )
Supplement: pmed.1002136.s018.xlsx › S6_Table
Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers.
Ahn JW et al.
Genome Medicine, 2014
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
21575214 (PubMed )
Supplement: 1476-4598-10-54-S3.XLS › mutations.txt
Select a paper to view details